GSK Partners With Myogen Ahead Of Ambrisentan Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline will commercialize Myogen’s selective endothelin receptor antagonist for pulmonary arterial hypertension outside the U.S. following approval; Myogen will take over marketing of GSK’s Flolan in the U.S.
You may also be interested in...
Gilead Submits NDA For Ambrisentan For PAH
Company has requested a priority review, but anticipates receiving a standard 10-month review, pushing the user fee date to Oct. 18.
Gilead Submits NDA For Ambrisentan For PAH
Company has requested a priority review, but anticipates receiving a standard 10-month review, pushing the user fee date to Oct. 18.
GSK/Myogen’s Flolan To Be Distributed Exclusively By Accredo
The pulmonary arterial hypertension therapy was previously available through Accredo and Caremark.